Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling Pathways

BACKGROUND: The FLT3/ITD mutation exists in many acute myeloid leukemia (AML) patients and is related to the poor prognosis of patients. In this study, we attempted to evaluate the antitumor activity of simvastatin, a member of the statin class of drugs, in vitro and in vivo models of FLT3/ITD AML a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Genhong, Yao, Jingwei, Lu, Zhen, Yu, Lian, Chen, Qinwei, Ding, Lihong, Fang, Zhihong, Li, Yin, Xu, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676344/
https://www.ncbi.nlm.nih.gov/pubmed/37847357
http://dx.doi.org/10.1007/s40268-023-00442-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676344/
https://www.ncbi.nlm.nih.gov/pubmed/37847357
http://dx.doi.org/10.1007/s40268-023-00442-6

Ejemplares similares